Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

BACKGROUND: Despite the recent development of new therapies, multiple myeloma (MM) remains an incurable disease. Thus, new, effective treatments are urgently needed, particularly for relapsed or refractory MM (RRMM). In an earlier phase I study, a novel form of recombinant human Apo2L/tumor necrosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Leng, Yun, Qiu, Lugui, Hou, Jian, Zhao, Yaozhong, Zhang, Xuejun, Yang, Shifang, Xi, Hao, Huang, Zhongxia, Pan, Ling, Chen, Wenming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016961/
https://www.ncbi.nlm.nih.gov/pubmed/27608772
http://dx.doi.org/10.1186/s40880-016-0140-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016961/
https://www.ncbi.nlm.nih.gov/pubmed/27608772
http://dx.doi.org/10.1186/s40880-016-0140-0

Ejemplares similares